Beyond denial: A case report illustrating the complexity of disengagement in advanced cancer care.

Palliat Support CareOct 26, 2026 (epub)

Julie Haslam, Anne-Sophie Morissette-Gravel, Laury Chamelian et al.

✦ AI-curated · Sources linked

Case in brief

A woman in her forties from Africa with advanced metastatic gastric cancer declined prognostic discussions, did not want her family informed, and avoided opioid analgesia. Although these behaviors were initially interpreted by her treating team as denial, she explicitly acknowledged her diagnosis and its severity. Psycho-oncology consultation reframed her choices as coherent with her values, maternal role, and cultural background rather than evidence of impaired insight or maladaptive coping. On the final day of her life, she accepted palliative care and agreed to family notification, illustrating that her apparent disengagement changed over time.

What made this case unusual

Behaviors resembling denial coexisted with explicit acknowledgment of the cancer’s severity; consultation linked her choices to personal values and cultural context rather than impaired insight.

Diagnostic / clinical pearl

Do not equate declining discussions or treatment with lack of insight. Assess the patient’s understanding, values, cultural context, and possible psychiatric or neurocognitive factors before interpreting disengagement as maladaptive denial.

Why it matters

Offering individualized, empathic care while respecting autonomy may allow patients to engage differently over time, without pathologizing their initial choices.

Source

Published in Palliat Support Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.